

[Click here to view linked References](#)

# 1 Corneal and Conjunctival Alteration of Innate Immune 2 Expression in First-Degree Relatives of Keratoconus Patients.

3 Uxía Regueiro PhD<sup>1,2</sup>, Maite López-López OD<sup>2</sup>, Pablo Hervella PhD<sup>1</sup>, Tomás Sobrino PhD<sup>1#</sup>, Isabel Lema MD  
4 PhD<sup>1,2,3#</sup>.

## 5 Author details:

6 <sup>1</sup> Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Santiago  
7 de Compostela, Spain.

8 <sup>2</sup> Facultade de Óptica e Optometría, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.

9 <sup>3</sup> Instituto Galego de Oftalmoloxía (INGO), Hospital Provincial de Conxo, Santiago de Compostela, Spain.

## 10 Address for correspondence #:

11 Prof. Isabel Lema

12 Instituto Galego de Oftalmoloxía

13 Hospital Provincial de Conxo

14 15706 - Santiago de Compostela (Spain)

15 E-mail: [mariaisabel.leva@usc.es](mailto:mariaisabel.leva@usc.es)

16 Phone & Fax number: (+34) 981951098

17 Dr. Tomás Sobrino

18 Clinical Neurosciences Research Laboratory

19 Hospital Clínico Universitario

20 15706 - Santiago de Compostela (Spain)

21 E-mail: [tomas.sobrino.moreiras@sergas.es](mailto:tomas.sobrino.moreiras@sergas.es)

22 Phone & Fax number: (+34) 981951098

23  
24 **ORCID:** Uxía Regueiro [0000-0001-9633-2701], Pablo Hervella [0000-0003-1249-6333], Tomás Sobrino [0000-  
25 0002-9760-8690], Isabel Lema [0000-0002-2894-0331].

26 **Type of submission:** Full Paper - Cornea.

27 **Acknowledgements:** This project has been awarded grants from the Spanish Ministry of Economy and  
28 Competitiveness (Instituto de Salud Carlos III: PI14/00247, PI18/00159); Xunta de Galicia (Consellería de Economía  
29 e Industria: IN607A2018/3), and the European Union program ERFD. T. Sobrino (CPII17/00027) is recipient of a  
30 research contract from the Miguel Servet Program (National Institute of Health Carlos III). Similarly, U. Regueiro was  
31 awarded a predoctoral Fellowship from the Xunta de Galicia (ED481A-2015/001). The funders had no role in the study  
32 design, data collection and analysis, decision to publish, or preparation of the manuscript.

## 33 Key messages:

- 34 • Corneal and conjunctival TLR2/TLR4 are overexpressed in eyes with KC.
- 35 • Corneal and conjunctival TLR2/TLR4 are overexpressed in first-degree relatives of KC patients.
- 36 • TLR2/TLR4 overexpression in KC relatives is not related to sex, age, and the presence or absence of allergic  
37 disease, eye itching and eye rubbing.
- 38 • TLR2/TLR4 expression in KC relatives is not related to abnormal clinical, topographic, aberrometric and  
39 tomographic parameters.

1      40    **ABSTRACT**

2  
3  
4      41    **Purpose:** The innate immune Toll-like receptors 2 (TLR2) and 4 (TLR4) may play a key role in the physiopathology  
5  
6      42    of keratoconus (KC). Therefore, the aim of this study was to compare TLR2/TLR4 expression in corneal and  
7  
8      43    conjunctival epithelial cells between healthy first-degree relatives of patients with KC and healthy controls as well as  
9  
10     44    KC patients.

11  
12     45    **Methods:** Case-control study in 72 healthy eyes of 36 control subjects, 53 eyes of 27 first-degree relatives and 109  
13  
14     46    eyes with KC (60 patients). All participants were subjected to a clinical, topographic, aberrometric and tomographic  
15  
16     47    examination with extraction of corneal and conjunctival epithelial cells through scraping. TLR2/TLR4 expression was  
17  
18     48    measured by flow cytometry, and was compared among controls, first-degree relatives and KC patients. The  
19  
20     49    relationship between TLRs expression and epidemiological-clinical variables or topographic-aberrometric-  
21  
22     50    tomographic parameters was also analyzed.

23  
24     51    **Results:** Mean TLR2/TLR4 expression showed a significant gradual increase among groups: controls< first-degree  
25  
26     52    relatives < KC patients. Mean expression of TLR2 in corneal epithelial cells and both TLR2/TLR4 in conjunctival  
27  
28     53    epithelial cells were significantly higher in relatives than in controls (p=0.026, p<0.001 and p=0.031, respectively).  
29  
30     54    Sex, age, allergic disease, eye itching, rubbing and topographic-aberrometric-tomographic parameters were not  
31  
32     55    associated to TLR2/TLR4 expression in relatives. TLR2 conjunctival expression was independently associated to  
33  
34     56    relatives (OR,1.001;CI95%,1.000-1.002,p=0.043) after adjustment by sex, age and rubbing.

35  
36     57    **Conclusion:** TLR2 and TLR4 are overexpressed in corneal and conjunctival epithelial cells of KC relatives compared  
37  
38     58    to controls. Both biomarkers may monitor early ocular changes in first-degree relatives who not show any abnormal  
39  
40     59    clinical-topographic-aberrometric-tomographic parameters.

41  
42      60  
43  
44     61    **Keywords:** Corneal and conjunctival epithelial cells, Innate immunity, Keratoconus, Relatives, Toll-like receptor 2  
45  
46     62    and 4.

## DECLARATIONS

**Funding:** This project has been awarded grants from the Spanish Ministry of Economy and Competitiveness (Instituto de Salud Carlos III: PI14/00247, PI18/00159); Xunta de Galicia (Consellería de Economía e Industria: IN607A2018/3), and the European Union program ERFD. T. Sobrino (CPII17/00027) is recipient of a research contract from the Miguel Servet Program (National Institute of Health Carlos III). Similarly, U. Regueiro was awarded a predoctoral Fellowship from the Xunta de Galicia (ED481A-2015/001). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Conflicts of interest/Competing interests:** The authors declare that they have no conflict of interest.

**Ethics approval and consent to participate:** This study was approved by the Ethics Committee for Clinical Research of Galicia, Spain (Code 2015/436).

**Consent for publication:** Not applicable.

**Availability of data and material:** The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Authors' contributions:** Conception and design of the study (T.S., I.L.). Data acquisition and analysis (U.R., M.L-L., P.H., T.S.). Clinical data acquisition and analysis (U.R., M.L-L., I.L.). Handled funding and supervision (T.S., I.L.). Statistical analysis (U.R., P.H.). Manuscript drafting (U.R., I.L.). Critical revision for important intellectual content (M.L-L., P.H., T.S.). Supervision (T.S., I.L.). All authors reviewed and approved the manuscript.

## List of abbreviations.

Arbitrary fluorescence units (AFUs), confidence interval (CI), corneal astigmatism (dK), diopters (D), dioptric central power (DCP), heat shock proteins (HSP), inferior-superior dioptric asymmetry (I-S asymmetry), interleukin 1beta (IL-1 $\beta$ ), interleukin 4 (IL-4), keratoconus (KC), maximum dioptric power (maxPD), micrometers ( $\mu$ m), minimum thickness point (MTP), nuclear factor-kappaB (NF- $\kappa$ B), odd ratio (OR), percentage (%), posterior elevation (PE), standard deviation (SD), steeper corneal meridian (K2), toll-like receptors (TLRs), toll-like receptor 2 (TLR2), toll-like receptor 4 (TLR4), tumor necrosis factor alpha (TNF- $\alpha$ ), vertical coma ( $Z_3^{\pm 1}$ ).

## 91 **Introduction**

92 The term “keratoconus” (KC) reflects a degenerative-chronic process characterized by the pathological  
93 weakening, thinning and protrusion of the corneal tissue [1]. Usually, it is a bilateral and asymmetric  
94 condition in which the distortion of the corneal curvature results in the appearance of irregular astigmatism  
95 and impaired vision [2], involving a significant public health problem [3-4]. KC has an early onset age,  
96 affecting young people in their second decade of life, and their evolution is often associated with itching  
97 and eye rubbing. Regarding the etiology, it has not been fully elucidated yet; nevertheless, KC is recognized  
98 as a disease associated with some environmental, biomechanical, genetic and biochemical mechanisms [5].

99 Several studies have confirmed the overexpression of inflammatory mediators measured in tears of KC  
100 patients, being this overexpression strongly correlated with the progression of the disease [6–8]. In line  
101 with the above, we have confirmed the overexpression of Toll-like Receptor 2 (TLR2) and 4 (TLR4) in  
102 corneal and conjunctival epithelial cells as well as in blood monocytes and neutrophils of KC patients [9-  
103 10]. TLR2 and TLR4 are both type I immune innate transmembrane proteins which detect the presence of  
104 exogenous and/or endogenous agents associated to cell damage [11]. Upon recognizing ligands, both TLRs  
105 trigger an immune response which contributes to the translocation of NF- $\kappa$ B factor to the nucleus and the  
106 subsequent expression of inflammatory genes [12]. It has been shown that the systemic innate immune  
107 overexpression observed in KC patients was correlated with the increase of inflammatory mediators and  
108 NF- $\kappa$ B factor in serum [10]. In addition, it was also confirmed a relationship between corneal and  
109 conjunctival expression of TLRs and the KC severity [9]. Consequently, we postulate that the alteration in  
110 the innate immune homeostasis acts at tissue level promoting an inflammatory response involving the  
111 molecular drivers that finally cause the tissue degradation in KC.

112 Moreover, genetic predisposition could also exacerbate the KC onset process. In this regard, the existence  
113 of families with several members affected of KC has described [13-14]. Regarding first-degree relatives,  
114 an incidence rate of KC up to 14% [15] and 19% [16] has been reported. In many cases, these first-degree  
115 relatives showed topographic corneal alterations [14-17]. For all these reasons, healthy first-degree relatives  
116 of patients with KC are considered a group of subjects with high probabilities to develop the disease.

1 118 In this study, we hypothesize that healthy first-degree relatives may show alterations in the expression of  
2  
3 119 TLR2 and/or TLR4. Therefore, the main aim of this study was to measure the TLR2/TLR4 expression in  
4  
5 120 corneal and conjunctival epithelial cells from healthy first-degree relatives of KC patients in comparison  
6  
7 121 with control subjects and KC patients. Moreover, we evaluated the relationship between TLR2/TLR4  
8  
9 122 expression and epidemiologic, clinic, topographic, aberrometric and tomographic parameters. To the best  
10  
11 123 of our knowledge, this is the first study that evaluates the implication of innate immunity receptors in first-  
12  
13 124 degree relatives of KC patients.  
14  
15  
16  
17

## 18 126 **Material and methods**

19  
20

21 127 The present study was performed following the principles of the Declaration of Helsinki of the World  
22  
23 128 Medical Association (as revised in Brazil 2013). All participants were subjected to a common clinical,  
24  
25 129 topographic, aberrometric, tomographic protocol with extraction of biological sample which was approved  
26  
27 130 by the Ethics Committee for Clinical Research of Galicia (Code 2015/436). All examinations were  
28  
29 131 conducted by the same researchers. Written informed consent was obtained from each participant prior to  
30  
31 132 their inclusion in the study and after full explanation of the procedures. The ophthalmological examination  
32  
33 133 included:

34  
35 134 (a) Filiation data and full anamnesis: sex, age, patient's eye history, family history of corneal ectasia  
36  
37 135 and medical history (allergy, eye itching, eye rubbing...). Atopic conditions such as rhinitis,  
38  
39 136 asthma and atopic dermatitis were included as allergic diseases as well as food allergies, drug  
40  
41 137 allergies, allergies to insect bites and animals. The presence or absence of eye itching and eye  
42  
43 138 rubbing was noted according to the users report.

44  
45 139 (b) Topographic and aberrometric parameters: dioptric central power (DCP), steper meridian (K2),  
46  
47 140 corneal astigmatism (dK), maximum dioptric power (maxDP), inferior-superior dioptric  
48  
49 141 asymmetry (I-S asymmetry) and high order aberrations in the anterior corneal surface [vertical  
50  
51 142 coma ( $Z_3^{\pm 1}$ ) and coma-like, for 6 mm of diameter]; collected using the TOPCON CA-100 System  
52  
53 143 corneal topographer (Topcon Medical Systems, Inc., USA).

54  
55 144 (c) Tomographic parameters: posterior elevation (PE) and minimum thickness point (MTP); collected  
56  
57 145 using Orbscan II corneal tomographer (Orbtek, USA).  
58  
59  
60  
61  
62  
63  
64  
65

1 146  
2  
3 147 At the end of the ophthalmological examination both corneal and conjunctival epithelial cell samples was  
4  
5 148 collected to determine the expression of TLR2 and TLR4:  
6  
7 149 (a) Sample collection: corneal and conjunctival epithelial cells was collected through superficial  
8  
9 150 scraping with ophthalmic surgical lancets of PVA (NETCELL, Network Medical Products Ltd,  
10  
11 151 UK), previously instilling an eye topic anesthetic (COLIRCUSÍ Double Anesthetics with  
12  
13 152 tetracaine at 0.1% and oxybuprocaine at 0.4%, ALCON CUSÍ SA, Spain). The corneal sample  
14  
15 153 was extracted from the lower third of the cornea and the conjunctival sample was conducted in the  
16  
17 154 lower bulbar conjunctive without touching the palpebral edge. Each ophthalmic lancet was put  
18  
19 155 into a sterile and nuclease-free cytometry tube with 1 mL of PBS. Superficial scraping performed  
20  
21 156 for sample collection was a non-injurious invasive technique which only induced mild  
22  
23 157 conjunctival hyperemia and/or mild superficial corneal staining during 1 or 2 hours after scraping.  
24  
25 158 (b) Sample analysis: TLR2/TLR4 expression was determined by Flow cytometry (Flow cytometer  
26  
27 159 FACS Aria iiu, BD Biosciences, USA; Software FACS Diva 6.02, BD Biosciences, USA),  
28  
29 160 following the same protocol described by Malfeito et al [9]. Epithelial cells were marked with 5µL  
30  
31 161 of fluorescein isothiocyanate anti-TLR2-conjugated monoclonal antibodies and with 5µL of  
32  
33 162 phycoerythrin anti-TLR4-conjugated monoclonal antibodies (INMUNOSTEP, Spain). To  
34  
35 163 homogenize the cytometry analysis in order to avoid that the density of cells had impact on  
36  
37 164 fluorescence intensity, a total of 1000 corneal events and 2000 conjunctival events were analyzed  
38  
39 165 following the method described by Malfeito et al [9]. Results were expressed in Arbitrary  
40  
41 166 Fluorescence Units (AFUs). Values have been adjusted to a negative control without antibodies.  
42  
43  
44

## 45 167 **Study subjects**

46  
47 168 This study included 123 subjects classified into three groups: 36 control subjects, 27 first-degree relatives  
48  
49 169 of KC patients and 60 patients with KC. All of them were recruited in the Instituto Galego de Oftalmoloxía  
50  
51 170 (INGO), Santiago de Compostela, Spain. The common inclusion criteria for all groups included: 1) signing  
52  
53 171 of informed consent form; 2) conjunctival hyperemia <2 (Nathan Efron scale) [18]; 3) Schirmer >15mm  
54  
55 172 in 5 minutes; and 4) at least 5 days with no contact lenses and no instillation of artificial tears or eye drops.  
56  
57 173 Specific inclusion criteria for controls and relatives included: 1) normal biomicroscopic examination and  
58  
59  
60  
61  
62  
63  
64  
65

1 174 2) normal topography, aberrometry and tomography parameters, with no irregular astigmatism or  
2  
3 175 abnormalities suggestive of corneal ectasia. Finally, the specific inclusion criterion for the KC group was  
4  
5 176 the positive diagnosis of KC: evaluated with slit lamp examination, corneal topography, aberrometry and  
6  
7 177 tomography [19–21].

8  
9  
10 178 On the other hand, common exclusion criteria for all groups included: 1) sickness or infection that interferes  
11  
12 179 with the molecular markers of innate immunity; 2) dry eye disease, 3) active ocular or systemic  
13  
14 180 inflammation (uveitis...); 4) local or systemic anti-inflammatory treatments; 5) recent eye surgery; 6)  
15  
16 181 traumatism or corneal-conjunctival disease; and/or 7) pregnancy. In addition, control subjects with family  
17  
18 182 history of KC were excluded.

### 21 183 **Statistical analysis**

22  
23  
24 184 Statistical analysis was made using SPSS 20.0 for Windows (IBM, USA). Results were expressed as  
25  
26 185 percentages for categorical variables and as mean ( $\pm$  standard deviation (SD)) for continuous quantitative  
27  
28 186 variables with normal distribution. The normality of a quantitative variable was verified by the  
29  
30 187 Kolmogorov-Smirnov test. The bivariate comparison of groups was made with chi-square test (categorical  
31  
32 188 variables) and with t-Student contrasts (normal continuous variables). The graphic representation of the  
33  
34 189 comparisons between normal continuous variables was made using error bars. The one-way ANOVA test  
35  
36 190 was used to make comparisons among more than two study groups (control, relatives and KC) following a  
37  
38 191 Bonferroni post-hoc test. Bivariate correlations were analyzed using Pearson's coefficient (for normal  
39  
40 192 distribution). In addition, a multivariable analysis strategy by logistic regression was carried out to correct  
41  
42 193 potential confounding factors (sex, age and eye rubbing) in controls and relatives. A value of  $p \leq 0.05$  was  
43  
44 194 considered statistically significant in all tests.

45  
46  
47 195 The statistical EPIDAT 3.1 software was used for calculating sample size. This determination was based in  
48  
49 196 preliminary non-published studies of TLR2 conjunctival levels. Accepting a confidence level of 95% ( $\alpha =$   
50  
51 197 0.05) and 75% power ( $\beta = 0.25$ ), at least 34 control eyes, 49 eyes of first-order relatives and 66 eyes with  
52  
53 198 KC would be necessary.

### 56 199 **Results**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 200 **Sample features**

201 We studied 72 healthy eyes from 36 control subjects (39% male; mean age,  $31.3 \pm 10.4$  years), 53 eyes of  
202 27 first-degree relatives of KC patients (58% male; mean age,  $25.4 \pm 10.2$  years) and 109 eyes of 60 patients  
203 with KC (58% male; mean age,  $33.1 \pm 8.7$  years). The lower mean age in relatives compared to the KC  
204 group is due to the fact that relatives were siblings or offspring of KC patients.

205 **Table 1** shows the epidemiological-clinical characteristics and the topographic-aberrometric-tomographic  
206 parameters for each study group. Importantly, no statistically relevant differences were found in the  
207 percentage of allergic diseases. KC patients showed greater incidence of eye itching (85%) and  
208 consequently a greater rate of eye rubbing (80%) than the rest of the study subjects (controls and relatives).  
209 There were statistical differences between the pathological topographic, aberrometric and tomographic  
210 parameters of KC patients and the normal parameters of control and relatives groups. Therefore, our main  
211 study group (relatives) show totally normal epidemiological-clinical characteristics and topographic-  
212 aberrometric-tomographic parameters.

## 213 **TLR2 & TLR4 expression**

214 The mean ( $\pm$ SD) expression of TLR2/TLR4 in corneal and conjunctival epithelial cells for each study group  
215 is showed in **Table 1** and represented in **Figure 1**. Mean TLR2/TLR4 expression showed a gradual increase  
216 among groups: control subjects < relatives of KC patients < KC patients. Regarding the cornea, TLR2  
217 expression was significant higher in relatives than in controls ( $1054 \pm 772$  vs  $752 \pm 629$  ( $p=0.026$ ),  
218 respectively). The same trend was observed for the conjunctiva, where relatives showed a significant  
219 increase in TLR2 and TLR4 compared with the control group ( $1117 \pm 595$  vs  $806 \pm 412$  ( $p \leq 0.001$ ), and  
220  $3259 \pm 1305$  vs  $2669 \pm 1441$  ( $p=0.031$ ); respectively). However, only TLR2 expression in conjunctival  
221 epithelial cells was independently associated to relatives' group (OR, 1.001; CI95%, 1.000 to 1.002,  
222  $p=0.043$ ) after adjustment for sex, age and rubbing [**Table 2**].

223 KC patients showed significantly higher expression values in corneal and conjunctival TLR2/TLR4 than  
224 controls. Likewise, KC patients showed significantly higher TLR2/TLR4 expression than relatives; with  
225 the exception of conjunctival TLR2, which did not show statistical difference between KC group and  
226 relatives [**Table 1**].

1 227 **First-degree relatives: Relationship between TLR2/TLR4 expression and epidemiological-**  
2  
3 228 **clinical variables.**

4  
5  
6 229 Once we have demonstrated the overexpression of several TLRs in relatives compared to controls, the next  
7  
8 230 step was to analyze how epidemiological and clinical factors may influence the innate immune  
9  
10 231 overexpression in relatives. We carried out a bivariate study for each TLR in relatives according to sex, age  
11  
12 232 and the presence or absence of allergic disease, eye itching and eye rubbing [Table 3]. As a result, the  
13  
14 233 corneal and/or conjunctival TLR2/TLR4 expression did not show statistically significant differences with  
15  
16 234 these epidemiological-clinical variables. Therefore, in relatives, we did not observe an association between  
17  
18 235 TLRs expression and the sex, the age and the presence or absence of allergic disease, eye itching and eye  
19  
20 236 rubbing.

21  
22  
23 237 **First-degree relatives: Correlation between TLR2/TLR4 expression and topographic,**  
24  
25 238 **aberrometric and tomographic parameters.**

26  
27  
28  
29 239 Finally, we carried out a correlation study in order to evaluate the association between the topographic-  
30  
31 240 aberrometric-tomographic parameters and the TLR2/TLR4 expression in relatives [Table 4]. As result,  
32  
33 241 topographic (DCP, K2, dK, maxDP, I-S), aberrometric ( $Z_3^{\pm 1}$ , coma-like) and tomographic (PE, MTP)  
34  
35 242 parameters did not show statistical correlation with the expression of TLR2/TLR4 in corneal and/or  
36  
37 243 conjunctival epithelial cells in the relatives group.

38  
39  
40 244

## 41 42 43 245 **Discussion**

44  
45  
46  
47 246 In this study we have demonstrated that first-degree KC relatives, with healthy epidemiological-clinical  
48  
49 247 characteristics and normal topographic-aberrometric-tomographic parameters, show overexpression of  
50  
51 248 corneal TLR2 and conjunctival TLR2/TLR4 compared with control subjects. However, only conjunctival  
52  
53 249 TLR2 was associated with relatives after adjustment by sex, age and eye rubbing. To the best of our  
54  
55 250 knowledge, this is the first study which evaluates the expression of innate immunity receptors in corneal  
56  
57 251 and conjunctival epithelial cells from first-degree relatives of KC patients. In line with our results, Malfeito

1 252 et al [9] also observed the corneal and conjunctival TLR2/TLR4 overexpression in KC and subclinical KC  
2  
3 253 compared with controls; confirming that corneal TLR2 expression may predict with high sensitivity and  
4  
5 254 specificity the probability of KC.  
6  
7  
8 255 TLR2 and TLR4 are immune innate transmembrane proteins that detect the presence of exogenous and/or  
9  
10 256 endogenous agents associated with cell damage [11]. Therefore, TLR2 and TLR4 can be activated by  
11  
12 257 infectious exogenous agents such as bacterial lipoproteins or lipopolysaccharides, and by endogenous  
13  
14 258 ligands such as cellular fibronectin, heat shock proteins (HSP), lactoferrin or proteins with hormonal  
15  
16 259 influence [22]. The TLR2/TLR4 activation by these ligands induces the expression of genes involved in  
17  
18 260 the inflammatory response. Consequently, the TLR2/TLR4 overexpression in the ocular surface of first-  
19  
20 261 degree KC relatives represents an ocular environment more predisposed to trigger a proinflammatory state,  
21  
22 262 which could lead to the KC onset. Due to the fact that conjunctival TLR2 is the highest overexpressed  
23  
24 263 receptor in KC relatives, but the corneal TLR2 is the main overexpressed receptor in patients with manifest  
25  
26 264 KC [9]; we may hypothesize that the disease predisposition begins at conjunctival level and could lead to  
27  
28 265 the disease pathological progression by the influence of multiple factors.  
29  
30  
31 266 We have demonstrated that TLRs expression in relatives is not related to sex, age and the presence or  
32  
33 267 absence of allergic disease, eye itching and eye rubbing. In addition, the topographic (DCP, K2, dK,  
34  
35 268 maxDP, I-S asymmetry), aberrometric ( $Z_3^{\pm 1}$ , coma-like) and tomographic (PE, MTP) parameters neither  
36  
37 269 showed statistical correlation with TLRs expression in relatives. In contrast, a strong association between  
38  
39 270 TLR2 and TLR4 expression with the severity of KC quantified by topographic, aberrometric and  
40  
41 271 tomographic parameters (steep meridian [K2], coma, minimum thickness point [MTP]) was observed in  
42  
43 272 KC patients [9]; demonstrating that the more advanced the disease is, the greater the expression of toll-like  
44  
45 273 receptors will be. The lack of relationship between the TLR2/TLR4 expression and the clinical-  
46  
47 274 epidemiological values or the topographic-aberrometric-tomographic parameters in healthy KC relatives,  
48  
49 275 confirms an exacerbated early innate immune predisposition at corneal and conjunctival level which may  
50  
51 276 contribute to the KC onset process. In this regard, similarly, Ionescu et al [23] found significantly increased  
52  
53 277 levels of interleukin 1 beta (IL-1 $\beta$ ) and interleukin 4 (IL-4) in the tears of KC patients and their first-degree  
54  
55 278 family members compared to normal subjects. IL-1 $\beta$  and IL4 has been widely recognized as cytokines  
56  
57 279 associated to immune and proinflammatory processes and to the KC pathogenesis [24–26]. These results  
58  
59  
60  
61  
62  
63  
64  
65

1 280 are consistent with a previous study in which the systemic TLR2 and TLR4 immune overexpression  
2  
3 281 observed in KC patients was correlated with the increase of inflammatory mediators and NF-kB factor in  
4  
5 282 serum [10].  
6  
7  
8 283 In the same way, the studies conducted by Kara et al [27] and by Ionescu et al [28] stated that the corneal  
9  
10 284 biomechanical properties are also altered in KC relatives even before that the topographic indices. They  
11  
12 285 propose that biomechanical parameter could be an early premonitory sign of a subclinical keratoconus [27-  
13  
14 286 28]. Although the primary keratoconus origin remains unknown, the corneal structural disturbance is  
15  
16 287 attributed to alterations in the entire ocular surface homeostasis [5]. Dogru et al [29] found several changes  
17  
18 288 in the ocular surface of KC patients, including squamous conjunctival metaplasia, low goblet cell density  
19  
20 289 and disorder of tear quality. In the same way, Ziangirova et al [30] reported the presence of immune  
21  
22 290 inflammation in the conjunctival tissue of KC patients. Therefore, taking all these results into account we  
23  
24 291 may hypothesize that the overexpression of the innate immune mechanisms in the corneal and the  
25  
26 292 conjunctival epithelial cells, as well as the tear proinflammatory process, could trigger the corneal  
27  
28 293 biomechanical alteration in first-degree relatives of KC patients.  
29  
30  
31 294 Considering that relatives of KC patients have the highest risk of developing the disease [16-31]; the  
32  
33 295 overexpression of innate immune receptors in the corneal and conjunctival epithelial surface, the expression  
34  
35 296 of proinflammatory molecules in tears, as well as the evaluation of the corneal biomechanical capacities  
36  
37 297 should acquire great importance as preoperative evaluations in these subjects, instead of the topographic-  
38  
39 298 aberrometric-tomographic diagnostic methods currently used. It could avoid postoperative keratoectasia in  
40  
41 299 relatives who wish to perform refractive surgery. Consequently, in order to bring this study closer to clinical  
42  
43 300 practice, a device is currently being developed to test the TLR2/TLR4 expression in the ocular surface. This  
44  
45 301 device will allow to carried out an easier and faster procedure different to the flow cytometry and the  
46  
47 302 superficial epithelial scraping. Moreover, the findings of this study open the possibility to design new  
48  
49 303 preventive or therapeutic approaches. Blocking or immunomodulating the TLR2 and/or TLR4 would at  
50  
51 304 least decrease the typical proinflammatory state in the ocular surface of the KC patients. In addition, future  
52  
53 305 studies could also focus on the importance of following these healthy first-degree relatives over time to  
54  
55 306 identify who is progressing in KC development and determine if there is a correlation between their TLR2/4  
56  
57 307 levels at the time baseline and disease development.  
58  
59  
60  
61  
62  
63  
64  
65

1 308

2

3

4 309 **Conclusion**

5

6

7

8 310 TLR2 and TLR4 are overexpressed in corneal and conjunctival epithelial cells of first-degree KC relatives

9

10 311 compared to control subjects. Therefore, these receptors (with in particular conjunctival TLR2 due to be

11

12 312 the highest overexpressed) may be useful to monitor early ocular changes in first-degree relatives with

13

14 313 healthy clinical values and with topographic, aberrometric and tomographic parameters inside the normal

15

16 314 limits. In addition, they may be also useful to asses if a subject is in risk of developing KC. Finally, further

17

18 315 studies are necessary in order to evaluate TLR2 and TLR4 as potential therapeutic targets for future

19

20 316 preventive treatments in KC.

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

## References

- 1 317  
2  
3  
4 318 [1] Belin MW, Asota IM, Ambrosio R, Khachikian SS (2011) What's in a name: keratoconus, pellucid  
5  
6 319 marginal degeneration, and related thinning disorders. *Am J Ophthalmol* 152:157–162.  
7  
8  
9 320 [2] Kymes SM, Walline JJ, Zadnik K et al (2008) Changes in the quality-of-life of people with  
10  
11 321 keratoconus. *Am J Ophthalmol* 145(4):611–617.  
12  
13  
14 322 [3] Godefrooij DA, Mangen MJJ, Chan E et al (2017) Cost-Effectiveness Analysis of Corneal Collagen  
15  
16 323 Crosslinking for Progressive Keratoconus. *Ophthalmology* 124:1485–1495.  
17  
18  
19 324 [4] Chan E, Baird PN, Vogrin S, Sundararajan V, Daniell MD, Sahebjada S (2020) Economic impact of  
20  
21 325 keratoconus using a health expenditure questionnaire: A patient perspective. *Clin Exp Ophthalmol*  
22  
23 326 48(3):287-300.  
24  
25  
26 327 [5] Mas Tur V, MacGregor C, Jayaswal R, O'Brart D, Maycock N (2017) A review of keratoconus:  
27  
28 328 Diagnosis, pathophysiology, and genetics. *Surv Ophthalmol* 62:770–783.  
29  
30  
31 329 [6] Kolozsvári BL, Petrovski G, Gogolák P et al (2014) Association between mediators in the tear fluid  
32  
33 330 and the severity of keratoconus. *Ophthalmic Res* 51(1):46–51.  
34  
35  
36 331 [7] Lema I, Duran J (2005) Inflammatory molecules in the tears of patients with keratoconus.  
37  
38 332 *Ophthalmology* 112(4):654–659.  
39  
40  
41 333 [8] Wisse RP, Kuiper JJ, Gans R, Imhof S, Radstake TR, Van der Lelij A (2015) Cytokine expression in  
42  
43 334 keratoconus and its corneal microenvironment: a systematic review. *Ocul Surf* 13(4):272–283.  
44  
45  
46 335 [9] Malfeito M, Regueiro U, Pérez-Mato M, Campos F, Sobrino T, Lema I (2019) Innate Immunity  
47  
48 336 Biomarkers for Early Detection of Keratoconus. *Ocul Immunol Inflamm.* 27:942-948.  
49  
50  
51 337 [10] Sobrino T, Regueiro U, Malfeito M, Vieites-Prado A, Pérez-Mato M, Campos F, Lema I (2017)  
52  
53 338 Higher expression of Toll-like receptors 2 and 4 in blood cells of keratoconus patients. *Sci Rep*  
54  
55 339 7:12975.  
56  
57  
58 340 [11] Takeda K, Akira S (2005) Toll-like receptors in innate immunity. *Int Immunol* 17:1–14.  
59  
60  
61 341 [12] Kawai T, Akira S (2007) TLR signaling. *Semin Immunol* 19(1):24–32.  
62  
63  
64  
65

1 342 [13] Rabinowitz YS (1998) Keratoconus. *Surv Ophthalmol* 42:297–319.

2

3

4 343 [14] Kaya V, Utine CA, Altunsoy M, Oral D, Yilmaz OF (2008) Evaluation of corneal topography with

5

6 344 Orbscan II in first-degree relatives of patients with keratoconus. *Cornea* 27:531–534.

7

8

9 345 [15] Zadnik K, Barr JT, Edrington TB et al (1998) Baseline Findings in the Collaborative Longitudinal

10

11 346 Evaluation of Keratoconus (CLEK) Study. *Invest Ophthalmol Vis Sci* 39:2537–2546.

12

13 347 [16] Awwad ST, Yehia M, Mehanna C-J, Fattah MA, Saad A, Hatoum A, Al-Haddad C (2019)

14

15 348 Tomographic and Refractive Characteristics of Pediatric First-Degree Relatives of Keratoconus

16

17 349 Patients. *Am J Ophthalmol* 207:71-76.

18

19

20 350 [17] Levy D, Hutchings H, Rouland JF et al (2004) Videokeratographic anomalies in familial keratoconus.

21

22 351 *Ophthalmology* 111:867–874.

23

24

25 352 [18] Efron N (1998) Grading scales for contact lens complications. *Ophthalmic Physiol Opt* 18:182–186.

26

27

28 353 [19] Fam H-B, Lim K-L (2006) Corneal elevation indices in normal and keratoconic eyes. *J Cataract*

29

30 354 *Refract Surg* 32:1281–1287.

31

32

33 355 [20] Krachmer JH, Feder RS, Belin MW (1984) Keratoconus and related noninflammatory corneal thinning

34

35 356 disorders. *Surv Ophthalmol* 28:293–322.

36

37

38 357 [21] Alió JL, Shabayek MH (2006) Corneal higher order aberrations: a method to grade keratoconus. *J*

39

40 358 *Refract Surg* 22:539–545.

41

42

43 359 [22] Zhang Z, Schluesener HJ (2006) Mammalian toll-like receptors: from endogenous ligands to tissue

44

45 360 regeneration. *Cell Mol Life Sci* 63:2901–2907.

46

47

48 361 [23] Ionescu IC, Corbu CG, Tanase C et al (2018) Overexpression of Tear Inflammatory Cytokines as

49

50 362 Additional Finding in Keratoconus Patients and Their First Degree Family Members. *Mediators*

51

52 363 *Inflamm* 2018:4285268.

53

54

55 364 [24] Akdis M, Burgler S, Cramer R et al (2011) Interleukins, from 1 to 37, and interferon- $\gamma$ : Receptors,

56

57 365 functions, and roles in diseases. *J Allergy Clin Immunol* 127:701-721.

58

59 366 [25] Sorkhabi R, Ghorbanihaghjo A, Taheri N, Ahoor MH (2015) Tear film inflammatory mediators in

60

61

62

63

64

65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

367 patients with keratoconus. *Int Ophthalmol* 35:467–472.

368 [26] Balasubramanian SA, Mohan S, Pye DC, Willcox MD (2012) Proteases, proteolysis and inflammatory  
369 molecules in the tears of people with keratoconus. *Acta Ophthalmol* 90:303–309.

370 [27] Kara N, Altinkaynak H, Baz O, Goker Y (2013) Biomechanical evaluation of cornea in  
371 topographically normal relatives of patients with keratoconus. *Cornea* 32:262–266.

372 [28] Ionescu IC, Corbu CG, Nicula C et al (2018) The importance of corneal biomechanics in assessing  
373 first degree family members of keratoconus patients. *Rom J Ophthalmol* 61:149–154.

374 [29] Dogru M, Karakaya H, Özçetin H et al (2003) Tear function and ocular surface changes in  
375 keratoconus. *Ophthalmology* 110:1110–1118.

376 [30] Ziangirova GG, Antonova OV (2002) The causes of necrobiosis and apoptosis of corneal epithelial  
377 cells during primary acquired keratoconus. *Izv Akad Nauk Serii Biol* 5:517–521.

378 [31] El-Khoury S, Abdelmassih Y, Hamade A et al (2016) Pediatric Keratoconus in a Tertiary Referral  
379 Center: Incidence, Presentation, Risk Factors, and Treatment. *J Refract Surg* 32:534-541.

1 380 **FIGURES**

2  
3  
4 381 **Figure 1.** Mean TLR2/TLR4 expression for each study group showing a significant gradual increase among  
5  
6 382 groups: controls < first-degree relatives < KC patients.

7  
8 383 **Statistical differed with regard to:** † controls, § all groups. [P-values are showed in Table 1].

9  
10 384 **Sample size:** Control= 72 eyes; Relatives= 53 eyes; KC= 109 eyes.

11 385 **Abbreviations:** KC, keratoconus; TLR2, toll-like receptor 2; TLR4, toll-like receptor 4; AFU, arbitrary fluorescence units.

12 386

13  
14  
15  
16 387 **TABLES**





17  
18  
19 388 **Table 1.** Epidemiological-clinical characteristics, topographic-aberrometric-tomographic parameters and  
20  
21 389 TLR2/TLR4 expression in corneal and conjunctival epithelial cells for each study group.

22  
23  
24 390 **Table 2.** Crude and adjusted OR of relative´s group for TLR expression.

25  
26  
27 391 **Table 3.** Mean expression ( $\pm$ SD) of TLR2/TLR4 in corneal and conjunctival epithelial cells of first-degree  
28  
29 392 relatives according to their epidemiological (sex and age) and clinical (allergic disease, itching and rubbing)  
30  
31 393 characteristics.

32  
33  
34  
35 394 **Table 4.** Correlation (Pearson´s coefficient) between TLR2/TLR4 expression and quantitative topographic,  
36  
37 395 aberrometric and tomographic parameters in first-degree relatives of patients with KC.

38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



**TABLE.1.** Epidemiological-clinical characteristics, topographic-aberrometric-tomographic parameters and TLR2/TLR4 expression in corneal and conjunctival epithelial cells for each study group.

	Control	Relatives	<i>P</i> <sup>†</sup>	KC	<i>P</i> <sup>†</sup>	<i>P</i> <sup>‡</sup>
Sex, males (%)	38.9	57.7	0.138	58.3	0.066	0.957
Age, years	31.3 ± 10.4	25.4 ± 10.2	<b>0.032</b>	33.1 ± 8.7	0.353	<b>0.003</b>
Allergic disease (%)	47.2	42.3	0.707	60.0	0.228	0.133
Itching (%)	27.8	39.2	0.185	82.6	<b>&lt;0.0001</b>	<b>&lt;0.0001</b>
Rubbing (%)	33.3	35.3	0.823	71.6	<b>&lt;0.0001</b>	<b>&lt;0.0001</b>
DCP (D)	44.05 ± 1.65	44.30 ± 1.14	0.353	49.19 ± 5.67	<b>&lt;0.0001</b>	<b>&lt;0.0001</b>
K2 (D)	44.32 ± 1.75	44.54 ± 1.22	0.439	49.42 ± 4.28	<b>&lt;0.0001</b>	<b>&lt;0.0001</b>
dK (D)	0.84 ± 0.66	0.97 ± 0.74	0.298	3.75 ± 2.21	<b>&lt;0.0001</b>	<b>&lt;0.0001</b>
maxDP (D)	44.72 ± 1.80	45.21 ± 1.66	0.122	53.30 ± 5.33	<b>&lt;0.0001</b>	<b>&lt;0.0001</b>
I-S asymmetry (D)	-0.09 ± 0.51	-0.18 ± 0.57	0.400	5.69 ± 3.75	<b>&lt;0.0001</b>	<b>&lt;0.0001</b>
Z <sub>3</sub> <sup>+1</sup> (μm)	0.29 ± 0.15	0.26 ± 0.13	0.378	3.34 ± 9.92	<b>0.01</b>	<b>0.028</b>
Coma-like (μm)	0.35 ± 0.14	0.34 ± 0.14	0.774	4.33 ± 17.23	<b>0.049</b>	<b>0.040</b>
PE (μm)	28.0 ± 9.8	28.7 ± 12.3	0.730	94.7 ± 41.9	<b>&lt;0.0001</b>	<b>&lt;0.0001</b>
MTP (μm)	556 ± 37	537 ± 51	0.083	453 ± 62	<b>&lt;0.0001</b>	<b>&lt;0.0001</b>
TLR2 cornea (AFU)	752 ± 629	1054 ± 772	<b>0.026</b>	2402 ± 1819	<b>&lt;0.0001</b>	<b>&lt;0.0001</b>
TLR4 cornea (AFU)	1768 ± 1163	1962 ± 693	0.325	4172 ± 2018	<b>&lt;0.0001</b>	<b>&lt;0.0001</b>
TLR2 conjunctiva (AFU)	806 ± 412	1117 ± 595	<b>&lt;0.001</b>	1357 ± 1035	<b>&lt;0.0001</b>	0.164
TLR4 conjunctiva (AFU)	2669 ± 1441	3259 ± 1305	<b>0.031</b>	4374 ± 1723	<b>&lt;0.0001</b>	<b>&lt;0.0001</b>

**Note:** Significant *P*-values are given in bold.

**Sample size:** Control= 36 subjects, 72 eyes; Relatives= 27 subjects, 53 eyes; KC= 60 patients, 109 eyes.

**Abbreviations:** KC, keratoconus; DCP, dioptric central power; K2, steeper corneal meridian; dK, corneal astigmatism; maxDP, maximum dioptric power; I-S asymmetry, inferior-superior dioptric asymmetry; Z<sub>3</sub><sup>+1</sup>, vertical coma; PE, posterior elevation; MTP, minimum thickness point; TLR2, toll-like receptor 2; TLR4, toll-like receptor 4; AFU, arbitrary fluorescence units.

*P*<sup>†</sup> compared to control group.

*P*<sup>‡</sup> compared to relatives' group.

**TABLE.2.** Crude and adjusted OR of relative's group for TLR expression.

	<b>OR (CI95%), p</b>	<b>OR (CI95%), adjusted p</b>
<b>TLR2 cornea</b>	1.00 (1.00 to 1.00), <b>p=0.042</b>	1.00 (1.00 to 1.00), p=0.599
<b>Sex</b>		0.49 (0.15 to 1.57), p=0.231
<b>Age</b>		0.95 (0.89 to 1.01), p=0.111
<b>Rubbing</b>		1.19 (0.33 to 4.35), p=0.788
	<b>OR (CI95%), p</b>	<b>OR (CI95%), adjusted p</b>
<b>TLR2 conjunctiva</b>	1.00 (1.00 to 1.00), <b>p=0.004</b>	1.00 (1.00 to 1.00), <b>p=0.043</b>
<b>Sex</b>		0.46 (0.13 to 1.56), p=0.210
<b>Age</b>		0.95 (0.90 to 1.02), p=0.152
<b>Rubbing</b>		1.20 (0.33 to 4.30), p=0.780
	<b>OR (CI95%), p</b>	<b>OR (CI95%), adjusted p</b>
<b>TLR4 conjunctiva</b>	1.00 (1.00 to 1.00), <b>p=0.038</b>	1.00 (1.00 to 1.00), p=0.304
<b>Sex</b>		0.50 (0.15 to 1.61), p=0.245
<b>Age</b>		0.95 (0.89 to 1.01), p=0.113
<b>Rubbing</b>		1.43 (0.42 to 4.91), p=0.571

Crude and adjusted OR of relatives' group for TLR expression.

**Note:** Significant P-values are given in bold. Dependent variable was the study group (control or relatives).

**Sample size:** Control= 36 subjects, 72 eyes; Relatives= 27 subjects, 53 eyes.

**Abbreviations:** CI, confidence interval; OR, odds ratio; TLR2, toll-like receptor 2; TLR4, toll-like receptor 4.

**TABLE.3.** Mean expression ( $\pm$ SD) of TLR2/TLR4 in corneal and conjunctival epithelial cells of first-degree relatives according to their epidemiological (sex and age) and clinical (allergic disease, itching and rubbing) characteristics.

		TLR2 cornea	TLR4 cornea	TLR2 conjunctiva	TLR4 conjunctiva
<b>Sex</b>	<b>Male</b>	807 $\pm$ 440	1595 $\pm$ 565	1201 $\pm$ 685	3278 $\pm$ 1250
	<b>Female</b>	1268 $\pm$ 1381	2162 $\pm$ 775	1200 $\pm$ 764	2835 $\pm$ 1401
	<b>P</b>	0.288	0.067	0.998	0.455
<b>Age</b>	<b><math>\leq 24</math> years</b>	725 $\pm$ 309	1837 $\pm$ 870	1305 $\pm$ 696	3158 $\pm$ 1213
	<b><math>\geq 25</math> years</b>	1312 $\pm$ 1322	1839 $\pm$ 515	1086 $\pm$ 725	3011 $\pm$ 1455
	<b>P</b>	0.168	0.993	0.488	0.804
<b>Allergic disease</b>	<b>No</b>	1148 $\pm$ 1185	2015 $\pm$ 773	1385 $\pm$ 745	3123 $\pm$ 1094
	<b>Yes</b>	772 $\pm$ 364	1551 $\pm$ 499	901 $\pm$ 535	3031 $\pm$ 1668
	<b>P</b>	0.397	0.148	0.127	0.880
<b>Itching</b>	<b>No</b>	880 $\pm$ 434	2023 $\pm$ 661	962 $\pm$ 497	3329 $\pm$ 1565
	<b>Yes</b>	1213 $\pm$ 1059	1874 $\pm$ 773	1287 $\pm$ 693	3126 $\pm$ 992
	<b>P</b>	0.178	0.509	0.088	0.635
<b>Rubbing</b>	<b>No</b>	879 $\pm$ 426	1996 $\pm$ 644	989 $\pm$ 485	3284 $\pm$ 1507
	<b>Yes</b>	1256 $\pm$ 1114	1898 $\pm$ 815	1286 $\pm$ 737	3170 $\pm$ 1047
	<b>P</b>	0.134	0.668	0.126	0.793

**Sample size:** Relatives= 27 subjects, 53 eyes.

**Abbreviations:** TLR2, toll-like receptor 2; TLR4, toll-like receptor 4.

**TABLE 4.** Correlation (Pearson's coefficient) between TLR2/TLR4 expression and quantitative topographic, aberrometric and tomographic parameters in first-degree relatives of patients with KC.

	(Pearson correlation coefficient)								
	DCP	K2	dK	maxDP	I-S	Z <sub>3</sub> <sup>-1</sup>	Coma-like	PE	MTP
<b>TLR2 cornea</b>	(-0.160) 0.050	(-0.128) 0.094	(-0.158) 0.051	(-0.097) 0.160	(-0.147) 0.064	(0.086) 0.188	(0.064) 0.254	(0.135) 0.082	(-0.020) 0.417
<b>TLR4 cornea</b>	(-0.082) 0.200	(-0.061) 0.266	(-0.023) 0.408	(-0.027) 0.389	(-0.128) 0.093	(0.013) 0.447	(0.048) 0.312	(0.058) 0.274	(0.098) 0.157
<b>TLR2 conjunctiva</b>	(-0.135) 0.081	(-0.154) 0.055	(-0.060) 0.266	(-0.108) 0.133	(0.014) 0.443	(0.061) 0.264	(0.042) 0.331	(-0.020) 0.420	(-0.149) 0.062
<b>TLR4 conjunctiva</b>	(-0.105) 0.138	(-0.127) 0.095	(-0.131) 0.087	(-0.100) 0.151	(0.027) 0.388	(0.138) 0.076	(0.118) 0.110	(-0.131) 0.087	(-0.095) 0.164

**Sample size:** Relatives= 53 eyes.

**Abbreviations:** DCP, dioptric central power; K2, steeper corneal meridian; dK, corneal astigmatism; maxDP, maximum dioptric power; I-S asymmetry, inferior-superior dioptric asymmetry; Z<sub>3</sub><sup>-1</sup>, vertical coma; PE, posterior elevation; MTP, minimum thickness point; TLR2, toll-like receptor 2; TLR4, toll-like receptor 4.